Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916153 | 0.84 | POLB (0.43) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL711475 | 0.84 | PLA2G2A (0.39) | KMT2APOLBMEN1ALDH1A1SLC6A4 | |
| SCHEMBL915366 | 0.83 | ALDH1A1 (0.36) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL916292 | 0.82 | P2RX3 (0.38) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL916625 | 0.81 | SLC6A2 (0.39) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL916135 | 0.80 | KMT2A (0.35) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL916730 | 0.76 | BRD4 (0.39) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL916264 | 0.75 | ALDH1A1 (0.34) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL13356738 | 0.74 | MAPT (0.39) | MAPK1KMT2APOLBMEN1ALDH1A1 | |
| SCHEMBL916541 | 0.74 | MAPK1 (0.42) | MAPK1KMT2APOLBMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | MAPK1 3221/4885KMT2A 3473/4885POLB 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.